Neoadjuvant Nivolumab Shows Benefit in NSCLC

05:22 EDT 17 Apr 2018 | Medscape

Already used for nonresectable lung cancer, immunotherapy is now heading for the neoadjuvant niche, with nivolumab showing benefit when used before surgery.
Medscape Medical News

Original Article: Neoadjuvant Nivolumab Shows Benefit in NSCLC


More From BioPortfolio on "Neoadjuvant Nivolumab Shows Benefit in NSCLC"

Quick Search


Relevant Topics

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...

Surgical treatments
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...